We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI
Read MoreHide Full Article
Two medical sector stocks that are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list are Collegium Pharmaceutical (COLL - Free Report) and Masimo Corporation (MASI - Free Report) .
Correlated with the trend of rising earnings estimate revisions (EPS), Collegium has made its way onto the coveted strong buy list as an undervalued specialty pharmaceutical company that treats central nervous system, respiratory, and skin-related disorders.
Meanwhile, Masimo’s increased probability has become attractive as a provider of non-invasive health monitoring systems that provide real-time insight into patient physiology without the need for invasive procedures.
Collegium’s “A” Value Score
Magnifying Collegium’s steady growth is the pharmaceutical company’s “cheap” valuation, considering its top and bottom lines are expected to stretch 20% and 9% this year, respectively, and low-single digit growth marks are in the forecast for fiscal 2026.
The favorable trajectory makes Collegium stock look undervalued at just 5X forward earnings and under the optimum level of less than 2X sales. Trading well below the S&P 500’s averages, Collegium also offers a noticeable discount to its Zacks Medical-Drugs Industry average of 15.5X forward earnings and 3.4X forward sales.
Furthermore, in a crowded industry that includes more than 130 smaller-cap pharmaceutical drug companies, many are in speculative trial phases and aren’t profitable, whereas Collegium’s EPS projections have edged to over $7 per share.
Image Source: Zacks Investment Research
Masimo’s “A” Growth Score
Aforementioned, Masimo’s strong buy rating is highlighted by its increased profitability, with annual earnings expected to spike 20% in FY25 to $5.30 per share versus EPS of $4.40 last year.
Plus, FY26 EPS is projected to rise another 7% to $5.68. Starting to justify a slight P/E premium, Masimo stock trades at 26.5X forward earnings compared to its Zacks Medical-Instruments Industry average of 23.5X, with some noteworthy peers being Sonova Holding (SONVY - Free Report) and Alcon Inc. (ALC - Free Report) .
Image Source: Zacks Investment Research
Bottom Line
Seeing a nice spike in their EPS revisions over the last 60 days, Collegium and Masimo have become viable options in the portfolio for growth and value. Of course, the medical sector can also serve as a viable defensive hedge when market volatility arises, making these highly ranked stocks more attractive with the broader indexes near all-time highs.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI
Two medical sector stocks that are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list are Collegium Pharmaceutical (COLL - Free Report) and Masimo Corporation (MASI - Free Report) .
Correlated with the trend of rising earnings estimate revisions (EPS), Collegium has made its way onto the coveted strong buy list as an undervalued specialty pharmaceutical company that treats central nervous system, respiratory, and skin-related disorders.
Meanwhile, Masimo’s increased probability has become attractive as a provider of non-invasive health monitoring systems that provide real-time insight into patient physiology without the need for invasive procedures.
Collegium’s “A” Value Score
Magnifying Collegium’s steady growth is the pharmaceutical company’s “cheap” valuation, considering its top and bottom lines are expected to stretch 20% and 9% this year, respectively, and low-single digit growth marks are in the forecast for fiscal 2026.
The favorable trajectory makes Collegium stock look undervalued at just 5X forward earnings and under the optimum level of less than 2X sales. Trading well below the S&P 500’s averages, Collegium also offers a noticeable discount to its Zacks Medical-Drugs Industry average of 15.5X forward earnings and 3.4X forward sales.
Furthermore, in a crowded industry that includes more than 130 smaller-cap pharmaceutical drug companies, many are in speculative trial phases and aren’t profitable, whereas Collegium’s EPS projections have edged to over $7 per share.
Image Source: Zacks Investment Research
Masimo’s “A” Growth Score
Aforementioned, Masimo’s strong buy rating is highlighted by its increased profitability, with annual earnings expected to spike 20% in FY25 to $5.30 per share versus EPS of $4.40 last year.
Plus, FY26 EPS is projected to rise another 7% to $5.68. Starting to justify a slight P/E premium, Masimo stock trades at 26.5X forward earnings compared to its Zacks Medical-Instruments Industry average of 23.5X, with some noteworthy peers being Sonova Holding (SONVY - Free Report) and Alcon Inc. (ALC - Free Report) .
Image Source: Zacks Investment Research
Bottom Line
Seeing a nice spike in their EPS revisions over the last 60 days, Collegium and Masimo have become viable options in the portfolio for growth and value. Of course, the medical sector can also serve as a viable defensive hedge when market volatility arises, making these highly ranked stocks more attractive with the broader indexes near all-time highs.